- Home
- BEAT vs ESLA Comparison
BEAT vs ESLA Comparison
Compare BEAT & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAT
- ESLA
- Stock Information
- Founded
- BEAT 2015
- ESLA 2021
- Country
- BEAT United States
- ESLA United States
- Employees
- BEAT N/A
- ESLA N/A
- Industry
- BEAT Retail: Computer Software & Peripheral Equipment
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BEAT Technology
- ESLA Health Care
- Exchange
- BEAT Nasdaq
- ESLA Nasdaq
- Market Cap
- BEAT 33.1M
- ESLA 35.5M
- IPO Year
- BEAT 2021
- ESLA N/A
- Fundamental
- Price
- BEAT $1.03
- ESLA $0.91
- Analyst Decision
- BEAT Buy
- ESLA Strong Buy
- Analyst Count
- BEAT 1
- ESLA 1
- Target Price
- BEAT $8.00
- ESLA $16.00
- AVG Volume (30 Days)
- BEAT 118.9K
- ESLA 16.0K
- Earning Date
- BEAT 08-13-2025
- ESLA 08-25-2025
- Dividend Yield
- BEAT N/A
- ESLA N/A
- EPS Growth
- BEAT N/A
- ESLA N/A
- EPS
- BEAT N/A
- ESLA N/A
- Revenue
- BEAT N/A
- ESLA N/A
- Revenue This Year
- BEAT N/A
- ESLA N/A
- Revenue Next Year
- BEAT N/A
- ESLA N/A
- P/E Ratio
- BEAT N/A
- ESLA N/A
- Revenue Growth
- BEAT N/A
- ESLA N/A
- 52 Week Low
- BEAT $0.91
- ESLA $0.63
- 52 Week High
- BEAT $3.48
- ESLA $1.78
- Technical
- Relative Strength Index (RSI)
- BEAT 40.15
- ESLA 55.05
- Support Level
- BEAT $0.91
- ESLA $0.84
- Resistance Level
- BEAT $1.32
- ESLA $0.92
- Average True Range (ATR)
- BEAT 0.12
- ESLA 0.05
- MACD
- BEAT 0.01
- ESLA 0.01
- Stochastic Oscillator
- BEAT 29.27
- ESLA 75.90
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.